PRGN-2012 is an adenovirus vector-based gene therapy expected to induce immune responses against HPV 6 or 11 infected cells. Findings showed among those treated at the recommended PRGN-2012 dose ...

PRGN-2012 uses a gorilla adenovirus vector to deliver gene therapy to elicit robust T-cell immunity specific to HPV 6 or 11. A second gene therapy candidate that spurs antigen-specific T cell ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

They can employ either recombinant viruses, such as adenovirus ... can also rely on off-the-shelf plasmid and viral vector solutions, such as those offered by Charles River as a part of their gene ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

The adenoviridae family is divided into two genera: aviadenovirus, which causes disease in birds, and mastadenovirus, which infects a wide range of species, including humans. Human adenoviruses ...

Future Oncol. 2009;5(3):339-357. Clinical trials of oncolytic adenoviral gene therapy in ovarian cancer are due to commence shortly. They will proffer valuable data on toxicity and safety and the ...

and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity ...